328 related articles for article (PubMed ID: 17287460)
21. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
Lachmann RH
Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
[TBL] [Abstract][Full Text] [Related]
22. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
[TBL] [Abstract][Full Text] [Related]
23. Effects of cell-permeable ceramides and tumor necrosis factor-alpha on insulin signaling and glucose uptake in 3T3-L1 adipocytes.
Wang CN; O'Brien L; Brindley DN
Diabetes; 1998 Jan; 47(1):24-31. PubMed ID: 9421370
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells.
Bieberich E; Freischütz B; Suzuki M; Yu RK
J Neurochem; 1999 Mar; 72(3):1040-9. PubMed ID: 10037475
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
Norris-Cervetto E; Callaghan R; Platt FM; Dwek RA; Butters TD
J Biol Chem; 2004 Sep; 279(39):40412-8. PubMed ID: 15263008
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury.
Dupre TV; Doll MA; Shah PP; Sharp CN; Siow D; Megyesi J; Shayman J; Bielawska A; Bielawski J; Beverly LJ; Hernandez-Corbacho M; Clarke CJ; Snider AJ; Schnellmann RG; Obeid LM; Hannun YA; Siskind LJ
J Lipid Res; 2017 Jul; 58(7):1439-1452. PubMed ID: 28490444
[TBL] [Abstract][Full Text] [Related]
27. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.
Abe A; Arend LJ; Lee L; Lingwood C; Brady RO; Shayman JA
Kidney Int; 2000 Feb; 57(2):446-54. PubMed ID: 10652021
[TBL] [Abstract][Full Text] [Related]
28. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes.
Zhao H; Przybylska M; Wu IH; Zhang J; Siegel C; Komarnitsky S; Yew NS; Cheng SH
Diabetes; 2007 May; 56(5):1210-8. PubMed ID: 17470562
[TBL] [Abstract][Full Text] [Related]
29. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
30. The sirtuin inhibitor cambinol reduces intracellular glucosylceramide with ceramide accumulation by inhibiting glucosylceramide synthase.
Ishibashi Y; Ito M; Hirabayashi Y
Biosci Biotechnol Biochem; 2020 Nov; 84(11):2264-2272. PubMed ID: 32705968
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents.
Kang W; Hong HJ; Guan J; Kim DG; Yang EJ; Koh G; Park D; Han CH; Lee YJ; Lee DH
Metabolism; 2012 Mar; 61(3):424-33. PubMed ID: 21945106
[TBL] [Abstract][Full Text] [Related]
32. Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase.
Overkleeft HS; Renkema GH; Neele J; Vianello P; Hung IO; Strijland A; van der Burg AM; Koomen GJ; Pandit UK; Aerts JM
J Biol Chem; 1998 Oct; 273(41):26522-7. PubMed ID: 9756888
[TBL] [Abstract][Full Text] [Related]
33. A chemical genetic screen reveals that iminosugar inhibitors of plant glucosylceramide synthase inhibit root growth in Arabidopsis and cereals.
Rugen MD; Vernet MMJL; Hantouti L; Soenens A; Andriotis VME; Rejzek M; Brett P; van den Berg RJBHN; Aerts JMFG; Overkleeft HS; Field RA
Sci Rep; 2018 Nov; 8(1):16421. PubMed ID: 30401902
[TBL] [Abstract][Full Text] [Related]
34. Hepatic glycosphingolipid deficiency and liver function in mice.
Jennemann R; Rothermel U; Wang S; Sandhoff R; Kaden S; Out R; van Berkel TJ; Aerts JM; Ghauharali K; Sticht C; Gröne HJ
Hepatology; 2010 May; 51(5):1799-809. PubMed ID: 20432257
[TBL] [Abstract][Full Text] [Related]
35. Induction of glucosylceramide synthase by synthase inhibitors and ceramide.
Abe A; Radin NS; Shayman JA
Biochim Biophys Acta; 1996 Feb; 1299(3):333-41. PubMed ID: 8597588
[TBL] [Abstract][Full Text] [Related]
36. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
37. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
38. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Huang WC; Tsai CC; Chen CL; Chen TY; Chen YP; Lin YS; Lu PJ; Lin CM; Wang SH; Tsao CW; Wang CY; Cheng YL; Hsieh CY; Tseng PC; Lin CF
FASEB J; 2011 Oct; 25(10):3661-73. PubMed ID: 21705667
[TBL] [Abstract][Full Text] [Related]
39. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
40. Adipocytes harbor a glucosylceramide biosynthesis pathway involved in iNKT cell activation.
Rakhshandehroo M; van Eijkeren RJ; Gabriel TL; de Haar C; Gijzel SMW; Hamers N; Ferraz MJ; Aerts JMFG; Schipper HS; van Eijk M; Boes M; Kalkhoven E
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Aug; 1864(8):1157-1167. PubMed ID: 31051284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
